Knight Therapeutics Inc T.GUD

Pipeline of Drugs ... very light in Canada

[MrMugsy]

Thanks again for the clarification on the pipeline information.

The pipeline makes one thing clear ... we have no prospects for Canada at pre-approval.
We do have fairly new revenue generators in Canada though ... Imvexxy, Bijuva and Exelon.

We are sitting at 11 actual DrugxCountries  in our pipeline:
Tafasitamab x 5 countries (all but Canada)
Pemigatinib x 5 countries (all but Canada)
Halaven - Columbia - thyroid

Approvals are now the early-stage revenue generators at Knight and we have
10 DrugxCountries here:
Imvexxy - Canada
Bijuva - Canada
Halaven - Columbia - breast
Lenvima - Columbia
Exelon - 6 geographies (though marketed, Exelon is in early stage sales for Knight - unique situation)

[gudisgood]

Regarding Imvexxy and Bijuva, those will be launched in 2023. Lenvima and Halaven will be launched "early 2022". The Incyte drugs will be submitted in 2022, so launch likely in 2023. I'd imagine that, for now, with many products/markets in a launch/growth phase, and with Exelon transferring over soon as well, we have our hands full with the current portfolio for the time being. The

[MrMugsy]

[MrMugsy]

That's the beauty of what's being built here - the potential of ROW. The wider the GUD web is built (eventually to include Eastern Europe and/or S-E Asia) ... the locations where we can find drugs, drug portfolios and smaller pharma partnerships will also grow. Currencies will play into the calculation for prioritizing these opportunities . The wider the GUD web, the larger the